Weng Desheng, Calderwood Stuart K, Gong Jianlin
Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA.
Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Methods Mol Biol. 2018;1709:359-369. doi: 10.1007/978-1-4939-7477-1_26.
We have developed an enhanced molecular chaperone-based vaccine through rapid isolation of Hsp70 peptide complexes after the fusion of tumor and dendritic cells (Hsp70.PC-F). In this approach, the tumor antigens are introduced into the antigen processing machinery of dendritic cells through the cell fusion process and thus we can obtain antigenic tumor peptides or their intermediates that have been processed by dendritic cells. Our results show that Hsp70.PC-F has increased immunogenicity compared to preparations from tumor cells alone and therefore constitutes an improved formulation of chaperone protein-based tumor vaccine.
我们通过在肿瘤细胞与树突状细胞融合后快速分离热休克蛋白70肽复合物(Hsp70.PC-F),开发出了一种增强型分子伴侣疫苗。在这种方法中,肿瘤抗原通过细胞融合过程被引入树突状细胞的抗原加工机制,因此我们可以获得已被树突状细胞加工的抗原性肿瘤肽或其中间体。我们的结果表明,与单独的肿瘤细胞制剂相比,Hsp70.PC-F具有更高的免疫原性,因此构成了一种改良的基于伴侣蛋白的肿瘤疫苗配方。